Experience

Davis Polk advised Visa Inc. on its SEC-registered offering of $500 million of 0.750% senior notes due 2027, $1 billion of 1.100% senior notes due 2031 and $1.75 billion of 2.000% senior…

Davis Polk advised the representatives of the underwriters in connection with the $511.5 million SEC-registered offering of 5,500,000 American Depositary Shares of BioNTech SE. In addition,…

Davis Polk advised the underwriters in connection with the offering of $2 billion aggregate principal amount of 1.300% bonds due July 22, 2030, issued by the Province of Alberta. The…

Davis Polk advised the sales agent in connection with an SEC-registered at-the-market offering by InflaRx N.V. of its shares of common stock for up to an aggregate amount of $50…

Davis Polk advised the representative of the initial purchasers in connection with a Rule 144A/Regulation S offering of an additional $300 million aggregate principal amount of 6.250%…

Davis Polk advised the underwriters in connection with the offering of $2.25 billion aggregate principal amount of 1.000% bonds due May 20, 2025, issued by the Province of Alberta. The…

Davis Polk advised ADC Therapeutics SA on its SEC-registered initial public offering of 14,082,475 common shares, which included the exercise in full by the underwriters of their option to…

Davis Polk advised the representatives of the underwriters in connection with an SEC-registered offering by Ingredion Incorporated of $600 million aggregate principal amount of 2.900%…

Davis Polk advised the underwriters in connection with the $55 million initial public offering of 3,666,667 shares of common stock of Ayala Pharmaceuticals, Inc. Ayala is traded on the…

Davis Polk advised ADC Therapeutics SA in connection with its entry into a facility agreement with Deerfield Partners, L.P., pursuant to which Deerfield agreed to extend senior secured…